Market Intelligence
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Adalimumab Expectations Revised In The Wake Of Amgen Launch
The launch of Amgen’s Amjevita, the first US biosimilar rival to Humira, has been accompanied by multiple fresh forecasts of how competition could play out this year, with a host of further biosimilar launches on the horizon.

Scale Of Off-Patent Savings Ramps Up As Impact Of Biologic LOEs Increases
IQVIA’s latest Global Use of Medicines report demonstrates the impact generics and biosimilars are set to have on global pharmaceutical spending, with losses of exclusivity expected to dampen spending growth over the next five years.

International Trade Groups Call For Regulators To Protect Off-Patent Industry From Inflation
Rising inflation has exacerbated pressures in the off-patent drug sector, prompting Medicines for Europe and the US Association for Accessible Medicines to call for regulatory intervention to ensure the long-term sustainability of the space.

UK Prices Double For Multiple Molecules In December
Average trade prices for multiple products more than doubled in December in the UK, according to the latest figures from market researcher WaveData.

Organon Foresees US Adalimumab Discounts Hitting 80%-90%
Organon CEO Kevin Ali has suggested that discounts for US Humira biosimilars could “range anywhere between 80% and 90%” by 2025-2026, amid a slew of competition on adalimumab starting within weeks.

Humira In 2023: The $17bn Biosimilar Opportunity
The advent of US biosimilar competition to Humira in 2023 represents the largest ever loss-of-exclusivity opportunity for the off-patent industry, with the first adalimumab rival expected to hit the US market at the end of this month. But with a host of other biosimilars expected to launch throughout the year, how will competition play out in the long term?

UK Prices See A Raft Of Rises In November
Multiple treble-digit price rises were seen for UK generics in November as a lengthy list of price concessions was issued by the Department of Health and Social Care.

Regeneron ‘Shocked’ At Biogen Lucentis Biosimilar Sales
With its own interests in the branded eye-disease space, Regeneron has commented on ranibizumab biosimilar sponsor Biogen’s fortunes during a recent conference.

Humira LOE Is ‘Uncharted Territory’ As Fierce Competition Expected
Discussing the latest developments in the US biosimilars market, AmerisourceBergen’s senior director of biosimilar commercialization, Brian Biehn, talks about what we can expect from competition to Humira in 2023, how the first ophthalmology biosimilars are faring, and potential changes on the horizon at the FDA that could smooth the path to market for biosimilars sponsors.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.